Sanofi, Regeneron broaden alliance to find their next Dupixent
Source ↗
👁 0
💬 0
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
Comments (0)